Extension study to keep taking ocrelizumab for multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This extension study continues treatment with ocrelizumab for people with multiple sclerosis who are already taking it as part of a parent trial, to see how MS affects physical function over a longer time. It helps ensure you can keep receiving ocrelizumab even if it's not available where you live.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking ocrelizumab as part of one of the listed parent studies (CONSONANCE, MUSETTE, GAVOTTE, GLOBEAM, CONSONANCE Ext., O'HAND, OLERO, FENTREPID, MINTAKA, OCARINA I-SC, or OCARINA II-SC).
- It has been at least 5 months since your last treatment in the parent study, and the new study treatment will start after that time.
- If you could become pregnant, you must have a negative urine pregnancy test within 24 hours of your first dose in this extension study.
- You do not have access to ocrelizumab treatment through your local healthcare system or a company program.
- You have not permanently stopped your ocrelizumab treatment during the parent study or since then.
- You are not currently taking part in any other clinical trial (other than the parent study), and you do not have an active cancer, a weakened immune system, or other neurological disorders that could affect safety.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.